




# PHARMACEUTICAL 2019

Aeglea BioTherapeutics Inc.  
Rank 113 of 363





RealRate

# PHARMACEUTICAL 2019

Aeglea BioTherapeutics Inc.  
Rank 113 of 363



The relative strengths and weaknesses of Aeglea BioTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aeglea BioTherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Aeglea BioTherapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 163%, being 126% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	76,671
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,239
Liabilities, Non-Current	72
Other Assets	50
Other Compr. Net Income	75
Other Expenses	0
Other Liabilities	0
Other Net Income	1,115
Other Revenues	3,888
Property and Equipment	1,018
Research and Development	36,719
Selling, General and Administrative Expense	12,632

Output Variable	Value in 1000 USD
Assets	77,739
Liabilities	10,311
Expenses	49,351
Revenues	3,888
Stockholders Equity	67,428
Net Income	-44,348
Comprehensive Net Income	-44,310
Economic Capital Ratio	163%